CN-120121844-B - Application of interferon-induced transmembrane protein 1 in diagnosis of acute coronary syndrome

Abstract

The invention belongs to the technical field of biology, and particularly relates to application of interferon-induced transmembrane protein 1 in diagnosis of acute coronary syndrome. The present invention discloses the potential value of IFITM1 as a novel serum marker in the diagnosis of Acute Coronary Syndrome (ACS). First, the serum levels of IFITM1 in ACS patients were found to be significantly higher than in healthy and coronary heart disease patients by ELISA detection. Secondly, the level of the IFITM1 is related to the severity of coronary heart disease, and ROC analysis results show that AUC values of the IFITM1 in diagnosing CAD and ACS are 0.9530 and 0.9932 respectively, which shows that the IFITM1 has high diagnosis efficacy and can effectively distinguish ACS patients from other groups. The discovery of the IFITM1 provides a new auxiliary diagnosis means for clinic, and is helpful for early identifying ACS patients, so that treatment measures can be timely taken, and the prognosis of the patients can be improved.

Inventors

• HUANG QINGYAN
• HUANG QIONGHUI
• ZHONG ZHIXIONG
• HUANG MINGFENG
• ZHENG XIAOQI

Assignees

• 梅州市人民医院(梅州市医学科学院)

Dates

Publication Date

20260512

Application Date

20250224

Claims (4)

1. 1. Use of a reagent for detecting interferon-induced transmembrane protein 1 in the preparation of a product for diagnosing coronary artery disease; The detection sample of the product is a serum, plasma or tissue sample.
2. 2. The use according to claim 1, characterized in that: the reagent includes a reagent for detecting interferon-induced transmembrane protein 1 from a protein level or an RNA level.
3. 3. The use according to claim 2, characterized in that: The reagent for detecting the interferon-induced transmembrane protein 1 at the protein level is one or more reagents of a detection method selected from a chemiluminescence method, an immunofluorescence method, a protein chip method, a protein mass spectrometry method, an immunohistochemical method, a plaque tracing method based on a labeling technology, a western blotting method and an enzyme-linked immunosorbent assay; the reagent for detecting the interferon-induced transmembrane protein 1 at the RNA level is selected from one or more reagents of detection methods of high-throughput RNA sequencing, RNA-in-situ hybridization, digital PCR and fluorescent quantitative PCR.
4. 4. The use according to claim 1, characterized in that: the product comprises a detection kit, a detection chip or a detection test strip.

Description

Application of interferon-induced transmembrane protein 1 in diagnosis of acute coronary syndrome Technical Field The invention belongs to the technical field of biology, and particularly relates to application of interferon-induced transmembrane protein 1 in diagnosis of acute coronary syndrome. Background Acute coronary syndrome (acute coronary syndrome, ACS) is a clinical syndrome in which coronary atherosclerotic plaques rupture or erode, leading to thrombosis, thereby causing acute or subacute myocardial ischemia hypoxia. ACS has the characteristics of urgent onset, rapid progress, poor prognosis and the like, and is one of the main cardiovascular diseases threatening human health. Thus, early diagnosis and risk assessment of ACS are of great importance for improving patient prognosis. In clinical practice, the diagnosis of ACS requires a combination of patient clinical symptoms (e.g., chest pain), electrocardiographic results, cardiac enzymology, and coronary angiography findings. At present, there is no specific diagnostic index specific to ACS. Troponin I (cTnI) is an important serum marker currently widely accepted for diagnosing and distinguishing ACS and is elevated in the early stages (2-6 hours) after chest pain in patients. However, elevated troponin I can also be seen in other diseases such as viral myocarditis, heart failure, and chronic renal failure. D-dimers and C-reactive proteins, although associated with inflammation and stress, are not cardiac-specific because they are involved in a variety of pathophysiological processes. Coronary angiography is considered an authoritative method for diagnosing coronary stenosis, but as an invasive examination, it is expensive, and requires strict technical and equipment, which limits its acceptance and widespread use in patients to some extent. Therefore, a blood detection index with high specificity and sensitivity is sought, so that the early identification of ACS is facilitated, and the method has a vital meaning. In recent years, the use of serum markers in ACS diagnosis and risk assessment has received a great deal of attention. Research shows that traditional myocardial injury markers such as troponin, creatine kinase isozymes and the like have certain limitations in ACS early diagnosis. At present, a plurality of researches find a plurality of potential novel ACS serum markers, such as heart type fatty acid binding protein (H-FABP), growth differentiation factor-15 (GDF-15), angiotensin converting enzyme 2 (ACE 2) and the like. These markers have significantly increased expression levels in serum of ACS patients and are associated with disease severity, and are expected to be new indicators for ACS-assisted diagnosis and prognosis evaluation. However, the clinical application value of the markers still needs to be further verified at present. Interferon-induced transmembrane protein 1 (Interferon-Inducible Transmembrane Proteins, IFITM 1) is a member of the interferon-induced transmembrane protein family, which not only has antiviral function, but also up-regulates expression in a variety of tumors. At present, no clinical link between interferon-induced transmembrane protein 1 and ACS has been found in the prior art. Disclosure of Invention The invention aims to provide a novel marker for acute coronary integration, so as to solve the problem of insufficient sensitivity and specificity in the existing ACS diagnosis technology. By detecting and analyzing the protein level in the serum of a patient, the invention discovers that the expression of the IFITM1 in the serum of an ACS patient is increased, so that the invention provides a novel serum biomarker IFITM1 with higher specificity and sensitivity, thereby being convenient for accurately diagnosing in the early stage of ACS and reducing the situations of misdiagnosis and missed diagnosis. It is an object of a first aspect of the present invention to provide the use of IFITM1 as a marker in the diagnosis of acute coronary syndrome. It is an object of a second aspect of the present invention to provide the use of an agent for detecting IFITM1 in the manufacture of a product for diagnosing acute coronary syndrome. The object of the third aspect of the present invention is to provide a method for constructing a model for acute coronary syndrome. The object of the fourth aspect of the present invention is to provide a system for diagnosis of acute coronary syndrome. In order to achieve the above purpose of the present invention, the present invention adopts the following technical scheme: In a first aspect of the invention there is provided the use of IFITM1 (UniProt ID: P13164) as a marker in the diagnosis of acute coronary syndrome. In some embodiments of the invention, the acute coronary syndrome refers to a group of clinical syndromes based on pathological conditions with rupture or invasion of coronary atherosclerotic plaques, secondary complete or incomplete occlusive thrombosis, including